271 related articles for article (PubMed ID: 8613931)
1. Reversible inhibition of rat gastric H+/K+-ATPase by T-330, 2-[2-dimethylaminobenzyl)sulfinyl]-1-(3-methylpyridine-2-yl)imidazole.
Kinoshita M; Saito N; Noto T; Tamaki H
J Pharmacol Exp Ther; 1996 Apr; 277(1):28-33. PubMed ID: 8613931
[TBL] [Abstract][Full Text] [Related]
2. 2-[(2-Aminobenzyl)sulfinyl]-1-(2-pyridyl)-1,4,5,6-tetrahydrocyclopent[d]imidazoles as a novel class of gastric H+/K+-ATPase inhibitors.
Yamada M; Yura T; Morimoto M; Harada T; Yamada K; Honma Y; Kinoshita M; Sugiura M
J Med Chem; 1996 Jan; 39(2):596-604. PubMed ID: 8558532
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+,K+-ATPase.
Gedda K; Briving C; Svensson K; Maxvall I; Andersson K
Biochem Pharmacol; 2007 Jan; 73(2):198-205. PubMed ID: 17081503
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and pharmacological characteristics of a newly synthesized H+-K+ ATPase inhibitor, YJA20379-1, 2-amino-4,5-dihydro-8-phenylimidazole[2,1-b]thiazolo[5,4-g]benzothiazol e.
Sohn SK; Chang MS; Choi WS; Kim KB; Woo TW; Lee SB; Chung YK
Can J Physiol Pharmacol; 1999 May; 77(5):330-8. PubMed ID: 10535682
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of gastric H,K-ATPase activity and gastric epithelial cell IL-8 secretion by the pyrrolizine derivative ML 3000.
Smolka AJ; Goldenring JR; Gupta S; Hammond CE
BMC Gastroenterol; 2004 Feb; 4():4. PubMed ID: 15028114
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526).
Ito K; Kinoshita K; Tomizawa A; Inaba F; Morikawa-Inomata Y; Makino M; Tabata K; Shibakawa N
J Pharmacol Exp Ther; 2007 Oct; 323(1):308-17. PubMed ID: 17630360
[TBL] [Abstract][Full Text] [Related]
7. Sulfide and sulfoxide derivatives of substituted benzimidazoles inhibit acid formation in isolated gastric glands by different mechanisms.
Fryklund J; Wallmark B
J Pharmacol Exp Ther; 1986 Jan; 236(1):248-53. PubMed ID: 3001289
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+ -ATPase in vitro and in vivo.
Shin JM; Homerin M; Domagala F; Ficheux H; Sachs G
Biochem Pharmacol; 2006 Mar; 71(6):837-49. PubMed ID: 16405921
[TBL] [Abstract][Full Text] [Related]
9. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.
Kwon D; Chae JB; Park CW; Kim YS; Lee SM; Kim EJ; Huh IH; Kim DY; Cho KD
Arzneimittelforschung; 2001; 51(3):204-13. PubMed ID: 11304936
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of the K+-competitive H+,K+-ATPase inhibitor AZD0865 in isolated rat gastric glands.
Kirchhoff P; Andersson K; Socrates T; Sidani S; Kosiek O; Geibel JP
Am J Physiol Gastrointest Liver Physiol; 2006 Nov; 291(5):G838-43. PubMed ID: 16798725
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of gastric H+, K+-ATPase by 3-amino-5-methyl-2-(2-methyl-3-thienyl)imidazo[1,2-a]thieno[3,2-c]pyrid ine, SPI-447.
Ushiro T; Tsukimi Y; Tanaka H
Jpn J Pharmacol; 1997 Nov; 75(3):303-6. PubMed ID: 9434264
[TBL] [Abstract][Full Text] [Related]
12. Omeprazole has a dual mechanism of action: it inhibits both H(+)K(+)ATPase and gastric mucosa carbonic anhydrase enzyme in humans (in vitro and in vivo experiments).
Puscas I; Coltau M; Baican M; Domuta G
J Pharmacol Exp Ther; 1999 Aug; 290(2):530-4. PubMed ID: 10411559
[TBL] [Abstract][Full Text] [Related]
13. Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749.
Nagaya H; Satoh H; Kubo K; Maki Y
J Pharmacol Exp Ther; 1989 Feb; 248(2):799-805. PubMed ID: 2537417
[TBL] [Abstract][Full Text] [Related]
14. Antisecretory and antiulcer effect of T-330, a novel reversible proton pump inhibitor, in rats.
Kinoshita M; Saito N; Tamaki H
Eur J Pharmacol; 1997 Mar; 321(3):325-32. PubMed ID: 9085044
[TBL] [Abstract][Full Text] [Related]
15. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
Uchiyama K; Wakatsuki D; Kakinoki B; Takeuchi Y; Araki T; Morinaka Y
J Pharm Pharmacol; 1999 Apr; 51(4):457-64. PubMed ID: 10385219
[TBL] [Abstract][Full Text] [Related]
16. Novel indanyl-substituted imidazo[1,2-a]pyridines as potent reversible inhibitors of the gastric H+/K+-ATPase.
Zimmermann PJ; Buhr W; Brehm C; Palmer AM; Feth MP; Senn-Bilfinger J; Simon WA
Bioorg Med Chem Lett; 2007 Oct; 17(19):5374-8. PubMed ID: 17723299
[TBL] [Abstract][Full Text] [Related]
17. AHR-9294: a novel inhibitor of H,K-ATPase antagonizes gastric HCl secretion in vivo.
Reenstra WW; Pinkus LM; Bailey J; Smith WL; Droppleman D; Sancilio LF; Forte JG
J Pharmacol Exp Ther; 1992 May; 261(2):737-45. PubMed ID: 1315865
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the gastric H+,K+ -ATPase by plectrinone A, a diterpenoid isolated from Plectranthus barbatus Andrews.
Schultz C; Bossolani MP; Torres LM; Lima-Landman MT; Lapa AJ; Souccar C
J Ethnopharmacol; 2007 Apr; 111(1):1-7. PubMed ID: 17166678
[TBL] [Abstract][Full Text] [Related]
19. Omeprazole: mode of action and effect on acid secretion in animals.
Wallmark B
Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():101-6. PubMed ID: 2657278
[TBL] [Abstract][Full Text] [Related]
20. Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats.
Satoh H; Inatomi N; Nagaya H; Inada I; Nohara A; Nakamura N; Maki Y
J Pharmacol Exp Ther; 1989 Feb; 248(2):806-15. PubMed ID: 2537418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
